image of AnaptysBio team member
Focused on Patients The Anaptys Team works to transform patient health by delivering innovative immunology therapeutics. The Anaptys team works to transform patient health by delivering innovative immunology therapeutics.
Theresa, working in the Anaptys lab
image of AnaptysBio team members
Anaptys Overview A clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases. We are a clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases.
Sarah and Ben in an Anaptys conference room
image of 3D render of chemical compound
The Anaptys Difference Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance. Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance.
image of AnaptysBio team members
Transparency, Accountability, Humility Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives. Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives.
May and Annie, reviewing a recent Immunology publication
home-slide-2
Anaptys Thought Leadership Restoring Immune Homeostasis as a Development Approach to Treat and Modify Inflammatory Disease Restoring Immune Homeostasis as a Development Approach to Treat and Modify Inflammatory Disease Learn more from Anaptys' SVP Martin Dahl, Ph.D.

Press Releases

May 27, 2025
  • Anaptys News

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT.

May 5, 2025
  • Anaptys News

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.

March 24, 2025
  • Anaptys News

Anaptys Announces Stock Repurchase Plan

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share.

About

Science

Pipeline

Investors

Careers